UK's Hikma Pharmaceuticals reiterates 2026 outlook despite higher costs from Iran war

Hikma Pharmaceuticals reiterated its 2026 guidance, saying it expects to absorb higher shipping, energy, and insurance costs linked to the war in the Middle East. The update points to modest cost pressure rather than a change in outlook, with no revision to guidance announced. Market impact is likely limited unless the conflict further disrupts operations or raises input costs more materially.

Analysis

Hikma Pharmaceuticals reiterated its 2026 guidance, saying it expects to absorb higher shipping, energy, and insurance costs linked to the war in the Middle East. The update points to modest cost pressure rather than a change in outlook, with no revision to guidance announced. Market impact is likely limited unless the conflict further disrupts operations or raises input costs more materially.